An Observational Study of Chinese Multiple Myeloma Patients Treated With Velcade

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to acquire information on the usage, effectiveness, safety, and levels of health care resource utilization associated with Velcade therapy in recurrent and refractory multiple myeloma patients who are initiating Velcade and various combination therapies within the approved indication in a naturalistic setting.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xian-Janssen Pharmaceutical Ltd.
• Treatments: Bortezomib

Criteria

Inclusion Criteria:

• Must give informed consent in agreement with local legislation

• Must not have any contraindication listed in package insert

Exclusion Criteria:

• Patients currently participating in another investigational study of Velcade or any other medication

• Patients with severe hepatic or renal impairment

• Patients with platelet count below 25000/μl

• Patients who are considered disqualified for the study by the investigators